Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

36.04
-0.3600-0.99%
Post-market: 36.060.0200+0.06%19:59 EDT
Volume:14.69M
Turnover:531.60M
Market Cap:159.98B
PE:9.95
High:36.49
Open:36.31
Low:35.89
Close:36.40
52wk High:81.44
52wk Low:35.85
Shares:4.44B
Float Shares:3.19B
Volume Ratio:0.78
T/O Rate:0.46%
Dividend:1.72
Dividend Rate:4.78%
EPS(TTM):3.62
EPS(LYR):3.62
ROE:60.70%
ROA:17.43%
PB:5.60
PE(LYR):9.95

Loading ...

Novo Nordisk - Asking Court to Permanently Ban Hims From Selling Unapproved, Compounded Drugs That Infringe Patents, and Is Seeking to Recover Damages

THOMSON REUTERS
·
Feb 09

Novo Nordisk Sues Hims & Hers Over Alleged Patent Infringement on Compounded Semaglutide Products

Reuters
·
Feb 09

Novo Nordisk Shares Surge as Rival Abandons Low-Cost Wegovy Copycat Plan

Deep News
·
Feb 09

Hims & Hers Stock Plunges 15%. Why Losing the Novo Wegovy Battle Is a Blow. -- Barrons.com

Dow Jones
·
Feb 09

Barclays Remains a Hold on Novo Nordisk (0QIU)

TIPRANKS
·
Feb 09

HIMS Stock Drops, NVO Jumps after Hims & Hers Halts Selling $49 Wegovy Copy

TIPRANKS
·
Feb 09

Premarket Movers | Space Stocks Rally With Virgin Galactic up over 8%; AI Application Software Shares Gain With AppLovin up over 5%, Palantir up over 2%

Tiger Newspress
·
Feb 09

Stock Track | Novo Nordisk Soars 6.63% in Pre-Market as Hims & Hers Halts Competitive Weight-Loss Pill

Stock Track
·
Feb 09

Novo Nordisk Shares Rise As Hims Abandons $49 Weight-Loss Pill

Reuters
·
Feb 09

Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

Dow Jones
·
Feb 09

Novo Nordisk Faces Price War in Competitive Anti-Obesity Drug Market with No Relief in Sight

Deep News
·
Feb 09

24H | Big Techs Mostly Jump With Palantir, Oracle up Around 2%; Chip Shares Gain With Marvell, SOXL, SanDisk up over 2%; Novo Rallies 5%

Tiger Newspress
·
Feb 09

Stock Track | Novo Nordisk Soars 6.44% in Overnight Trading After FDA Action Against Rival's Wegovy Copy

Stock Track
·
Feb 09

Gartner, Stellantis, And Novo Nordisk Are Among Top 10 Large Cap Losers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio?

Benzinga
·
Feb 08

Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny -- Barrons.com

Dow Jones
·
Feb 08

The Weight-Loss Price Wars Are Breaking Big Pharma's Business Model -- Heard on the Street -- WSJ

Dow Jones
·
Feb 07

Review -- Barron's

Dow Jones
·
Feb 07

Health Care Up as Novo Nordisk Recoups Some Losses -- Health Care Roundup

Dow Jones
·
Feb 07

TrumpRx Is Here. Most People Won't Benefit. -- Barrons.com

Dow Jones
·
Feb 07

FDA Vows Swift Action Against Unapproved Drugs, Derailing HIMS' Weight-Loss Copycat Plan; Shares Drop Nearly 6%

Deep News
·
Feb 07